Document text
Principal Investigator: Connie Schmaljohn
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2022
Award: $43,684,432
Funding agency: National Institute of Allergy and Infectious Diseases
In FY22, the IRF-Frederick focused most research efforts on SARS-CoV-2/COVID-19 studies. This included in vitro testing of antibody therapeutics and development of nonhuman primate and hamster animal models of COVID-19 to support medical countermeasure efficacy testing and pathogenesis experiments. The IRF-Fredericks imaging capability has provided a unique, quantitative readout of lung disease in COVID-19 progression in these models.
In addition, the IRF-Frederick has continued to support a large number of academic, industrial, and NIH-intramural research program collaborators through established core capabilities, including clinical imaging, pathology, molecular virology, and clinical study support in Western Africa.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><Animal Disease Models><Animal Model><Animal Models and Related Studies><Animals><COVID-19><COVID-19 virus><COVID19><COVID19 virus><CV-19><CV19><Clinical><Clinical Research><Clinical Study><CoV-2><CoV2><Collaborations><Containment><Cricetinae><Disease><Disorder><Emerging Communicable Diseases><Emerging Infectious Diseases><Environment><Hamsters><Hamsters Mammals><Industrialization><Infectious Diseases / Laboratory><Infectious Diseases Research><Interdisciplinary Research><Interdisciplinary Study><Intramural Program><Intramural Research Program><Lung diseases><Medical Imaging><Mission><Modeling><Molecular Virology><Multidisciplinary Collaboration><Multidisciplinary Research><NIAID><NIH><National Institute of Allergy and Infectious Disease><National Institutes of Health><Pathogenesis><Pathology><Position><Positioning Attribute><Pulmonary Diseases><Pulmonary Disorder><Research><Research Resources><Research Support><Resources><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome related corona virus 2><Therapeutic antibodies><United States National Institutes of Health><Virulent><Virus><Western Africa><Wuhan coronavirus><base><clinical imaging><corona virus disease 2019><coronavirus disease 2019><coronavirus disease 2019 virus><coronavirus disease-19><coronavirus disease-19 virus><coronavirus infectious disease-19><disease of the lung><disorder of the lung><efficacy testing><experiment><experimental research><experimental study><hCoV19><imaging capabilities><in vitro testing><lung disorder><medical countermeasure><model of animal><model organism><nCoV2><non-human primate><nonhuman primate><novel><prevent><preventing><research facility><therapeutic agent development><therapeutic development><tool>